Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Cytarabine × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 52 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Burkitt Lymphoma 13 Myelodysplastic Syndromes 12 Leukemia, Biphenotypic, Acute 11 Leukemia 7 Recurrence 6 Lymphoma, Mantle-Cell 6 Lymphoma 5 Leukemia, Myelomonocytic, Chronic 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3 Myeloproliferative Disorders 3 Lymphoma, Large B-Cell, Diffuse 3 Neoplasm, Residual 2 Lymphoma, B-Cell 2 Leukemia, Myelomonocytic, Juvenile 2 Hematologic Neoplasms 2 Blastic Plasmacytoid Dendritic Cell Neoplasm 2 Vasculitis, Central Nervous System 1 Stiff-Person Syndrome 1 Sarcoma, Myeloid 1 Rasmussen subacute encephalitis 1 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1 Philadelphia Chromosome 1 Opsoclonus-Myoclonus Syndrome 1 Neuromyelitis Optica 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Cyclophosphamide 21 Rituximab 18 fludarabine 15 obinutuzumab 10 pirtobrutinib 9 fludarabine phosphate 9 venetoclax 8 ibrutinib 7 Prednisone 7 Lenalidomide 7 Biopsy 7 tocilizumab 6 glofitamab 6 Specimen Handling 6 Immunotherapy, Adoptive 6 polatuzumab vedotin 5 Mycophenolic Acid 5 Magnetic Resonance Spectroscopy 5 X-Rays 4 Tacrolimus 4 Phantoms, Imaging 4 Doxorubicin 4 pembrolizumab 3 palbociclib 3 olaparib 3 axicabtagene ciloleucel 3 Whole-Body Irradiation 3 Vincristine 3 Vemurafenib 3 Thiotepa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡